A Federal Circuit panel seemed skeptical of the government’s bid to overturn a decision allowing drugmaker Actavis to deduct $12 million it spent fending off lawsuits as it secured approval to sell generics, raising the question during oral arguments Friday whether the company was being uniquely targeted.
Fed. Circ. Panel Doubts Bid To Nix Actavis’ $12M Deduction
by usoftax_admin | Jun 7, 2024 | Tax News